Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tandem Diabetes Care (TNDM) Net Cash Flow (2016 - 2025)

Tandem Diabetes Care (TNDM) has disclosed Net Cash Flow for 13 consecutive years, with -$2.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Net Cash Flow fell 114.33% year-over-year to -$2.6 million, compared with a TTM value of $19.8 million through Dec 2025, up 117.21%, and an annual FY2025 reading of $19.8 million, up 117.21% over the prior year.
  • Net Cash Flow was -$2.6 million for Q4 2025 at Tandem Diabetes Care, down from $27.2 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $47.7 million in Q4 2022 and bottomed at -$50.4 million in Q3 2023.
  • Average Net Cash Flow over 5 years is -$380750.0, with a median of $2.8 million recorded in 2023.
  • Peak annual rise in Net Cash Flow hit 1051.86% in 2025, while the deepest fall reached 2680.52% in 2025.
  • Year by year, Net Cash Flow stood at -$41.3 million in 2021, then skyrocketed by 215.5% to $47.7 million in 2022, then tumbled by 144.41% to -$21.2 million in 2023, then surged by 185.11% to $18.0 million in 2024, then crashed by 114.33% to -$2.6 million in 2025.
  • Business Quant data shows Net Cash Flow for TNDM at -$2.6 million in Q4 2025, $27.2 million in Q3 2025, and $8.9 million in Q2 2025.